Neglecting plasma protein binding in COVID-19 patients leads to a wrong interpretation of lopinavir overexposure

Autor: Caroline Solas, E. Meriglier, Stéphane Bouchet, Françoise Stanke-Labesque, Elodie Gautier-Veyret, Carole Schwebel, Peggy Gandia, Zoubir Djerada, Olivier Epaulard, Guillaume Martin-Blondel, Stéphanie Ruiz, Didier Concordet, Fabrice Bonnet, Bruno Mourvillier

Publikováno v: Clinical Pharmacology & Therapeutics
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩
Clinical Pharmacology and Therapeutics, American Society for Clinical Pharmacology and Therapeutics, 2021, Therapeutic Innovations in Infectious Diseases, 109 (4), pp.1030-1033. ⟨10.1002/cpt.2196⟩

Boffito et al. recalled the critical importance to correctly interpret protein binding. Changes of lopinavir pharmacokinetics in coronavirus disease 2019 (COVID-19) are a perfect illustration. Indeed, several studies described that total lopinavir pl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a97f4bd4d018c78cd6f5d100aaabd7f9
http://hdl.handle.net/20.500.12278/26884